Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

An engineered influenza virus to deliver antigens for lung cancer vaccination

An Author Correction to this article was published on 13 July 2023

This article has been updated


The development of cancer neoantigen vaccines that prime the anti-tumor immune responses has been hindered in part by challenges in delivery of neoantigens to the tumor. Here, using the model antigen ovalbumin (OVA) in a melanoma model, we demonstrate a chimeric antigenic peptide influenza virus (CAP-Flu) system for delivery of antigenic peptides bound to influenza A virus (IAV) to the lung. We conjugated attenuated IAVs with the innate immunostimulatory agent CpG and, after intranasal administration to the mouse lung, observed increased immune cell infiltration to the tumor. OVA was then covalently displayed on IAV-CPG using click chemistry. Vaccination with this construct yielded robust antigen uptake by dendritic cells, a specific immune cell response and a significant increase in tumor-infiltrating lymphocytes compared to peptides alone. Lastly, we engineered the IAV to express anti-PD1-L1 nanobodies that further enhanced regression of lung metastases and prolonged mouse survival after rechallenge. Engineered IAVs can be equipped with any tumor neoantigen of interest to generate lung cancer vaccines.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Generation and characterization of live but non-productive IAVs with chimeric antigenic peptides.
Fig. 2: Endowing synthetic peptides with capability of robust uptake and DC maturation.
Fig. 3: Inducing strong immune responses and inflaming lung metastatic melanoma ‘hot’.
Fig. 4: Development of an all-in-one vector for synergizing PD-L1 inhibitor to repress lung metastases.
Fig. 5: An overview of PAPV-ICI platform for personalized cancer immunotherapy.

Data availability

The gene sequences of WSN influenza virus strain used in this study have been deposited in GenBank under accession numbers CY034138.1, CY034139.1, CY034135.1, CY034134.1, X17336.1, HE802059.1, L25818.1 and CY034136.1. Three-dimensional structures of HA have been deposited in the Protein Data Bank (PDB) with PDB ID 1RVT. All requests for raw and analyzed data and materials are promptly reviewed by our institution to verify whether the request is subject to any intellectual property or confidentiality obligations. Any data and materials that can be shared will be released via a material transfer agreement. All other data that support the findings of this study will be provided by the corresponding author upon reasonable request when possible. All data generated or analyzed during this study are included in the published article and its Supplementary Information files. Source data are provided with this paper.

Change history


  1. Alcazer, V. et al. Neoepitopes-based vaccines: challenges and perspectives. Eur. J. Cancer 108, 55–60 (2019).

    Article  PubMed  Google Scholar 

  2. Blass, E. et al. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215–229 (2021).

    Article  PubMed  Google Scholar 

  3. Yarchoan, M. et al. Targeting neoantigens to augment antitumour immunity. Nat. Rev. Cancer 17, 209–222 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Malonis, R. J., Lai, J. R. & Vergnolle, O. Peptide-based vaccines: current progress and future challenges. Chem. Rev. 120, 3210–3229 (2020).

    Article  CAS  PubMed  Google Scholar 

  5. Sellars, M. C., Wu, C. J. & Fritsch, E. F. Cancer vaccines: building a bridge over troubled waters. Cell 185, 2770–2788 (2022).

    Article  CAS  PubMed  Google Scholar 

  6. Sharma, P. et al. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer 11, 805–812 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Restifo, N. P. et al. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12, 269–281 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Daniel, S. At the bench: engineering the next generation of cancer vaccines. J. Leukoc. Biol. 108, 1435–1453 (2020).

    Article  Google Scholar 

  9. Bijker, M. S. et al. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur. J. Immunol. 38, 1033–1042 (2008).

    Article  CAS  PubMed  Google Scholar 

  10. Su, M. W. et al. Cognate peptide-induced destruction of CD8+ cytotoxic lymphocytes is due to fratricide. J. Immunol. 151, 658–667 (1993).

    Article  CAS  PubMed  Google Scholar 

  11. Audiger, C. et al. The importance of dendritic cells in maintaining immune tolerance. J. Immunol. 198, 2223–2231 (2017).

    Article  CAS  PubMed  Google Scholar 

  12. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5, 263–274 (2005).

    Article  CAS  PubMed  Google Scholar 

  13. Nicolas, A. et al. The clinical role of the TME in solid cancer. Br. J. Cancer 120, 45–53 (2019).

    Article  Google Scholar 

  14. Altorki, N. K. et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat. Rev. Cancer 19, 9–31 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Twumasi-Boateng, K. et al. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat. Rev. Cancer 18, 419–432 (2018).

    Article  CAS  PubMed  Google Scholar 

  16. Dock, G. The influence of complicating diseases upon leukaemia. Am. J. Med. Sci. 127, 563 (1904).

    Article  Google Scholar 

  17. Gerlach, T. et al. Recombinant influenza A viruses as vaccine vectors. Expert Rev. Vaccines 18, 379–392 (2019).

    Article  CAS  PubMed  Google Scholar 

  18. Sellers, S. A. et al. The hidden burden of influenza: a review of the extra- pulmonary complications of influenza infection. Influenza Other Respir. Viruses 11, 372–393 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  19. Kwong, J. C. et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N. Engl. J. Med. 378, 345–353 (2018).

    Article  PubMed  Google Scholar 

  20. Si, L. et al. Generation of influenza A viruses as live but replication-incompetent virus vaccines. Science 354, 1170–1173 (2015).

    Article  Google Scholar 

  21. Miller, C. L. et al. Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression. Cell Chem. Biol. 29, 451–462 (2022).

    Article  CAS  PubMed  Google Scholar 

  22. Giavazzi, R. et al. Syngeneic murine metastasis models: B16 melanoma. Methods Mol. Biol. 1070, 131–140 (2014).

    Article  CAS  PubMed  Google Scholar 

  23. Pump, K. K. Morphology of the acinus of the human lung. Dis. Chest 66, 126–134 (1969).

    Article  Google Scholar 

  24. Newman, J. H. et al. Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. Proc. Natl Acad. Sci. USA 117, 1119–1128 (2020).

    Article  CAS  PubMed  Google Scholar 

  25. Zhao, H. et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct. Target. Ther. 6, 263 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Helft, J. et al. Cross-presenting CD103+ dendritic cells are protected from influenza virus infection. J. Clin. Invest. 122, 4037–4047 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Ho, A. W. S. et al. Lung CD103+ dendritic cells efficiently transport influenza virus to the lymph node and load viral antigen onto MHC class I for presentation to CD8 T cells. J. Immunol. 187, 6011–6021 (2011).

    Article  CAS  PubMed  Google Scholar 

  28. Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540–1554 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Marofi, F. et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res. Ther. 12, 81 (2021).

    Article  PubMed  Google Scholar 

  31. Ripley, R. T. & Rusch, V. W. Lung metastases. In Abeloff’s Clinical Oncology 5th edn (eds Niederhuber, J. E. et al.) 64–777 (Saunders, 2013).

  32. Ferrucci, P. F. et al. Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancers (Basel). 13, 1383 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Bertrand, A. et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 13, 211 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  34. Weber, J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 12, 864–872 (2007).

    Article  CAS  PubMed  Google Scholar 

  35. Hamilton, J. R. et al. A recombinant antibody-expressing influenza virus delays tumor growth in a mouse model. Cell Rep. 22, 1–7 (2018).

    Article  CAS  PubMed  Google Scholar 

  36. Wandzik, J. M. et al. A structure-based model for the complete transcription cycle of influenza polymerase. Cell 181, 877–893 (2020).

    Article  CAS  PubMed  Google Scholar 

  37. Jorba, N. et al. Genetic trans-complementation establishes a new model for influenza virus RNA transcription and replication. PLoS Pathog. 5, e1000462 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  38. Vreede, F. T. et al. Model suggesting that replication of influenza virus is regulated by stabilization of replicative intermediates. J Virol. 78, 9568–9572 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references


We acknowledge the Department of Laboratory Animal Science at Peking University Health Science Center for assistance with animal experiments. We acknowledge Sangon Biotech Ltd., GeneWiz lnc. and Top Peptide Inc. for gene sequencing, plasmid construction and peptide synthesis. We thank B. Xu and relevant staff from the State Key Laboratory of Natural and Biomimetic Drugs for support of technical and experimental platforms. We thank C. Gong (Sichuan University) for gifting the B16-F10-OVA cell line and Y. Wang (Peking University) for gifting the 4T1-luci cell line. We thank Z. Jiang (Peking University) for support with flow cytometry technology; L. Zhang (Peking University) for support with transmission electron microscopy; and X. Yan (Xiamen University) for support with nanoflow work. This work was supported by the National Natural Science Foundation of China (grant no. 82130100 to D.Z., grant no. 81821004 to D.Z., grant no. 2017ZX09309009 to D.Z., grant no. 91753202 D.Z. and grant no. 82204258 to D.J.), the Ningbo Key Science and Technology Development Program (grant no. 2022Z136 to D.Z), the Ningbo Yongjiang Talent Introduction Program (grant no. 2022A-157-G to D.J.) and the China Postdoctoral Science Foundation (grant no. 2019M650394 to D.J. and grant no. BX20180017 to D.J.).

Author information

Authors and Affiliations



D.J. and Y.Z. designed and performed most experiments and analyzed the data. J.S. and B.Z. contributed to experimental designs and assisted with the experiments on immune cell identification in vitro and in vivo. W.M. and B.C. performed experiments with influenza virus. X.W., Y.L. and Z.C. assisted with animal efficacy evaluation. H.X. performed transgenic cell line construction. S.X., Q.W. and C.Z. contributed to the collection and assembly of data and polished the language. L.Z. provided comments. D.J. wrote the first draft of the paper. D.Z. and D.J. supervised all the experiments and revised the final manuscript. All of the authors reviewed the manuscript.

Corresponding authors

Correspondence to Dezhong Ji or Demin Zhou.

Ethics declarations

Competing interests

D.Z., D.J. and Y.Z. are inventors on relevant patent applications held by the Ningbo Institute of Marine Medicine, Peking University. The remaining authors declare no competing financial interests.

Peer review

Peer review information

Nature Biotechnology thanks Howard Kaufman and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Supplementary Figs. 1–22 and Supplementary Table 1.

Reporting Summary

Source data

Source Data Fig. 1

Statistical source data.

Source Data Fig. 2

Statistical source data.

Source Data Fig. 3

Statistical source data.

Source Data Fig. 4

Statistical source data.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ji, D., Zhang, Y., Sun, J. et al. An engineered influenza virus to deliver antigens for lung cancer vaccination. Nat Biotechnol (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research